Available IPD datapackage for study 'A Randomized Phase 3 Trial of Alimta (Pemetrexed) and Carboplatin Versus Etoposide and Carboplatin in Extensive-Stage Small Cell Lung Cancer'
收藏DataCite Commons2025-09-29 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/dataPackages/PR00005975.0
下载链接
链接失效反馈官方服务：
资源简介：
This study is a Phase 3, global, multi-center, open-label study of patients with extensive-stage small cell lung cancer. Eligible patients will be randomly assigned to receive either pemetrexed plus carboplatin or etoposide plus carboplatin. It is anticipated that pemetrexed plus carboplatin will offer similar survival benefits as compared to etoposide plus carboplatin.
提供机构：
Vivli
创建时间：
2025-09-29
